Mozzarc
Emerged
PAR and the Post Op Pain Patent - PPPP, of course....
Look, the addressing of OA is large...I mean really big, it affects around 10 to 15% of the Western Population, the percentages are higher amongst rural communities. Add in all the ACL injuries and sporting injuries and well....I don't need to say a lot. But tonight, something a little different, Post Operative Pain.
Special Thanks to the poster @Torpy on this one. What did he do? Well he was the one that pointed this patent out to us just after the patent was first listed a number of months ago.
This was yet another example of the goings on in the background that the average PAR investor doesn't know about, let alone any other investor. We are sneaking in well and truly under the radar here PAR folk...its going to be one hell of a journey in the future. Make sure you keep your ticket to ride, that precious ticket in the form of hard core shares. (My spec views).
POST OP STD OF CARE
Well that's simple, after surgery pain is usually managed via multiple pain reducing medications. It depends on what surgery and how much pain and is based on the individual.
The current 4 Basic groups of pain medications include:
All of the above have their disadvantages and in some cases can have side effects particularly with prolonged use.Opioids we know can be destructive and addictive in some cases.NSAIDS we also know can have many side effects and one such unwanted effect is a greater chance of potential joint degradation.
ASEPTIC PAIN
In this context, aseptic pain refers to pain that's occurs after surgery but is not linked to bacterial transmission.A peer review study2 of some 2,534 cases of total knee arthroplasty identified some 178 cases that were classified as having persistent aseptic pain post surgery.The groupings of observed pain was as follows:
As a rough we can calculate this ongoing pain represents about 7% of TKA's. Lets do a rough extrapolation, roughly around 750,000 TKA's performed per year...that's 7% of TKA's = 52,000 potential patients in this area alone. Maybe halve it to be conservative as not all may opt in for it? (More, no doubt, will opt in when it becomes std of care)...but the projected figures are so much more over the next lot of years...some 3.146 million TKA's by the year of 2040 and that's just the USA.3
What about ROW?
Oh, and one more addition to the above figures, the above doesn't include a single Hip replacement!
OUR PATENT
Filed in 2019 the patent (see Appendix below) covers Treatment of post-operative joint pain with polysulphated polysaccharides.
Much can actually be learned by reading through the patent as the background information on the product and its application is usually given Post Operative pain, according to the patent, occurs in about 20% of patients. Further, this pain can exist for up to and beyond a full year after surgery. Not a great place to be in. Imagine having to have pain killers for all that time and as the patent implies, this is "dissatisfying to the patient who has opted for joint autoplasty to reduce pain".
From an insurer point of view, this additional time spent in various clinics and hospitals and being seen by Doctors is a further impost on the medical system (Helllllo Insurers!).
So what can be done about this Post Op pain? Again the patent covers this and suggests that "Treatment of the aseptic persistent pain is reported to ultimately involve revision surgery."
Not ideal. However, it may not end there. Revision surgery can be complicated and comes with the risk that the pain will still subsist..."in some cases it can be detrimental". The problem with NSAIDS and corticosteroids is that these two in themselves have been linked to negative impacts on bone and cartilage. It sounds to me a spiralling downwards of further problems into the future in some cases. This is the standard of care...
The patent goes on to state that there are findings that implicate that PPS has potential effectiveness as a treatment option for patients suffering post operative pain.
THE EXAMPLE AND THE SURPRISE
To be honest, the below case example I have come across in the past....but there is an aspect that's new to me....lets investigate.
An example of a patient is given in the patent doc. This patient was suffering from degenerative OA in the left knee with BMELs present. They also were suffering from persistent pain following total right knee arthroplasty.
The patient was a 60 year old female and had previously end stage OA in her right knee which she then underwent the TKR. Subsequently, she also was recommended to have the same procedure done for her painful left knee. However, she joined the SAS program and amazingly found her pain in the natural left knee went from 8/10 to a 0/10.
In terms of function, her score went from 58/100 (fair) to 99/100 (excellent). Bone Marrow Endema Lesion size? Yes, as assessed by MRI there was a reduction in size.
This case example above I knew, what I didn't know about is the rest.
What was good about this observed reduction in size of BMEL was that the course of iPPS undertaken in this particular case was just two injections of iPPS per week for only 3 weeks! What I also didn't realise is the following.
As the patent doc itself exclaimed:
"Surprisingly, the post-operative aseptic, persistent pain in the right artificial knee joint also subsided/stopped and went to zero. The surprising improved pain response in the right knee was not consequent to the improvement in the left knee or was it associated with rehabilitation or compensatory to the improvement in the left knee".
Not only her pain went to zero in the left knee, a great result in itself, but her pain in and around the artificial right knee also went to zero! Addressing the post surgery aseptic pain.
We have also heard of patients having Rheumatoid Arthritis, as well as OA patients with multiple joints in pain and the course of iPPS having a reduction in pain in these multiple joints, concurrently.
Paradigmers...in the future, it is these such incredible miracle stories we are going to hear about over and over again....one day it wont just be us hearing it, it will be a much large population hearing, seeing and witnessing it too.
DYOR
APPENDIX
Patent - Post Op Pain
WIPO - Search International and National Patent Collections
patentscope.wipo.int
REFERENCES
1] https://www.mayoclinic.org/pain-medications/art-20046452
2] https://pubmed.ncbi.nlm.nih.gov/28261427/
3] https://www.rheumatologyadvisor.com...int-replacements-predicted-from-2020-to-2040/